

# ISCP



International Society of Cardiovascular Pharmacotherapy

For the first time, the **ANNUAL SCIENTIFIC MEETING OF THE INTERNATIONAL SOCIETY OF CARDIOVASCULAR PHARMACOTHERAPY (ISCP)** will come to the US for its **25<sup>TH</sup> congress!**

## ISCP 2020 PRELIMINARY PROGRAMME TOPICS

<b>Acute Coronary Syndromes</b>	<ul style="list-style-type: none"><li>• STEMI Culprit Lesion vs Complete revascularization</li><li>• Stents Bioreabsorbable Scaffolds</li><li>• Post PCI anticoagulants.</li><li>• Acute ischemic stroke. Novel approaches</li></ul>
<b>The Challenges of controlling blood pressure</b>	<ul style="list-style-type: none"><li>• Non-Pharmacologic treatment. How much salt?</li><li>• Personalize blood pressure target. Digital medicine</li><li>• Obesity and hypertension. The dual threat</li></ul>
<b>New Concepts on Atrial Fibrillation</b>	<ul style="list-style-type: none"><li>• Pharmacologic treatment (Who, How, When)</li><li>• The role of Anticoagulation in atrial fibrillation</li></ul>
<b>Prevention of Cardiovascular Disease</b>	<ul style="list-style-type: none"><li>• Atherosclerosis and lipid management</li><li>• Diet and prevention of atherosclerosis</li><li>• Meet the experts:<ol style="list-style-type: none"><li>1) Management of heart failure: Role of sacubitril valsartan</li><li>2) Anticoagulation in atrial fibrillation: when and how</li><li>3) Resistant hypertension: diagnosis and management</li><li>4) Digital Monitoring in hypertension</li><li>5) Sleep apnea management</li></ol></li></ul>
<b>Pulmonary Hypertension</b>	<ul style="list-style-type: none"><li>• Diagnosis and the role of RHC</li><li>• Management Pharmacological or Surgical</li></ul>
<b>Heart Failure with Preserved EF</b>	<ul style="list-style-type: none"><li>• Non-Pharmacologic management of HFpEF</li><li>• Therapies for HFpEF</li></ul>
<b>Point/Counterpoint</b>	<ul style="list-style-type: none"><li>• Management of HFmEF<ol style="list-style-type: none"><li>1) HFmEF should be treated as HFrEF</li><li>2) HFmEF should be treated as HFpEF</li></ol></li></ul>
<b>Panel Discussion Lipid therapy or Anti-inflammatory therapy for atherosclerosis</b>	<ul style="list-style-type: none"><li>• Lipid targets: HDL efflux capacity</li><li>• PCSK9- inhibitors (when)</li><li>• Inflammation and atherosclerosis a new target</li></ul>
<b>Henry N. Neufeld Memorial Award Lecture</b>	<ul style="list-style-type: none"><li>• Precision Medicine</li></ul>
<b>Cardiomyopathy update</b>	<ul style="list-style-type: none"><li>• Utilization of Biomarkers in Heart Failure</li><li>• Management Approach to Myocarditis</li><li>• Amyloid and new therapies</li></ul>
<b>Lecture</b>	<ul style="list-style-type: none"><li>• Hypertrophic Cardiomyopathy: Epidemiology and Management (B Maron)</li></ul>
<b>Heart failure update</b>	<ul style="list-style-type: none"><li>• Guideline therapy for heart failure in clinical practice</li><li>• Present and future therapies for heart failure</li><li>• Targeting myocardial fibrosis in HFpEF</li></ul>
<b>Peripheral Arterial and venous Disease</b>	<ul style="list-style-type: none"><li>• Management of PAD</li><li>• Management of Deep Venous Thrombosis</li><li>• Diagnosis and Management of Pulmonary Thromboembolic disease</li></ul>

For registration and abstract presentation, please consult our website: [www.iscp2020.com](http://www.iscp2020.com)

For further information, please contact:

Kim Ly, Project Manager - [kly@overcome.eu](mailto:kly@overcome.eu) - Tel: +33 (0)1 40 88 97 97

Overcome: Official PCO for ISCP 2020 - 13-15 rue des Sablons, 75116 PARIS - France

# www.iscp2020.com

MAY 8-9  
2020

Miami